亚虹医药：核心品种APL-1702获批上市，公司发展迈入新阶段-20260311

Investment Rating - The report maintains a "Buy" investment rating for the company [1] Core Insights - The approval of the core product APL-1702 marks a new stage in the company's development, with significant commercial preparations already in place for its market launch [5] - APL-1702, branded as 希维她®/CEVIRA®, is a pioneering photodynamic therapy product aimed at treating patients with cervical intraepithelial neoplasia (CIN2), addressing a substantial unmet clinical need in non-invasive treatment options [6] - The company is actively pursuing international market opportunities, having received acceptance from the European Medicines Agency and reached an agreement with the FDA on the clinical design for U.S. market entry [5] Financial Performance - The company forecasts revenues of 277 million yuan in 2025, representing a year-on-year growth of 37.49%, driven by the commercialization of existing products [7] - The net profit attributable to the parent company is projected to be -419 million yuan for 2025, reflecting ongoing high R&D investments and preparations for new product commercialization [8] - Revenue projections for 2025-2027 are 277 million, 501 million, and 803 million yuan respectively, with net profits expected to improve from -419 million to -149 million yuan over the same period [8][10] Market Demand - There is a significant unmet clinical demand for non-invasive treatments for cervical intraepithelial neoplasia, with over 700,000 diagnosed HSIL patients in China, of which approximately 60% are CIN2 cases [6] - The World Health Organization's initiative to eliminate cervical cancer aligns with the company's goals, as China aims for a 90% treatment rate for cervical cancer and precancerous lesions by 2030 [6] Commercialization Strategy - The company is implementing a "Commercialization 2.0" strategy, which has shown effectiveness with continuous growth in generic drug sales [5] - The successful launch of APL-1702 is expected to significantly enhance the company's revenue, alongside the ongoing growth of its generic drug portfolio [8]